> top > docs > PMC:7264098 > spans > 10367-13684 > annotations

PMC:7264098 / 10367-13684 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T209 244-252 SP_7 denotes COVID-19
T210 424-429 UBERON:0007023 denotes adult
T211 515-530 CHEBI:52217;CHEBI:52217 denotes pharmacological
T212 591-596 NCBITaxon:10239 denotes viral
T213 616-640 CHEBI:67079;CHEBI:67079 denotes anti-inflammatory agents
T214 708-716 GO:0035376 denotes entry of
T215 721-726 NCBITaxon:10239 denotes virus
T216 770-775 NCBITaxon:10239 denotes viral
T217 776-783 SO:0000704 denotes genetic
T218 802-808 UBERON:0002405;GO:0006955 denotes immune
T219 809-817 GO:0006955 denotes response
T220 897-905 SP_10 denotes SARS-CoV
T221 910-918 SP_9 denotes MERS-CoV
T222 1102-1110 SP_10 denotes SARS-CoV
T223 1277-1286 DG_29 denotes ribavirin
T224 1356-1360 SP_9 denotes MERS
T225 1582-1587 SP_6;NCBITaxon:9606 denotes human
T226 1642-1648 NCBITaxon:9606 denotes people
T227 1868-1890 CHEBI:52217;CHEBI:52217 denotes pharmacological agents
T228 1912-1920 SP_7 denotes COVID-19
T229 2082-2086 CHEBI:23888;CHEBI:23888 denotes drug
T230 2137-2142 NCBITaxon:10239 denotes viral
T231 2176-2180 CHEBI:23888;CHEBI:23888 denotes drug
T232 2315-2330 CHEBI:50858;CHEBI:50858 denotes corticosteroids
T233 2354-2368 GO:0019814 denotes immunoglobulin
T234 2441-2456 CHEBI:50858;CHEBI:50858 denotes corticosteroids
T235 2499-2507 SP_7 denotes COVID-19
T236 2587-2592 NCBITaxon:10239 denotes viral
T237 2695-2703 SP_10 denotes SARS-CoV
T238 2708-2716 SP_9 denotes MERS-CoV
T239 2781-2789 SP_7 denotes COVID-19
T240 2814-2818 PR:000001393 denotes IL-6
T241 2830-2838 GO:0042571 denotes antibody
T242 2840-2851 DG_35 denotes Tocilizumab
T243 2881-2887 UBERON:0001969 denotes plasma
T244 3094-3098 UBERON:0002048;GO:0030324 denotes lung
T245 3099-3105 UBERON:0000479;GO:0048771 denotes tissue
T246 3106-3112 GO:0006281 denotes repair
T247 3219-3228 CL:0000034 denotes stem cell
T248 3268-3276 SP_7 denotes COVID-19
T249 3291-3302 UBERON:0001004 denotes respiratory
T19107 244-252 SP_7 denotes COVID-19
T18999 424-429 UBERON:0007023 denotes adult
T82295 515-530 CHEBI:52217;CHEBI:52217 denotes pharmacological
T38095 591-596 NCBITaxon:10239 denotes viral
T83805 616-640 CHEBI:67079;CHEBI:67079 denotes anti-inflammatory agents
T45166 708-716 GO:0035376 denotes entry of
T6847 721-726 NCBITaxon:10239 denotes virus
T60882 770-775 NCBITaxon:10239 denotes viral
T38954 776-783 SO:0000704 denotes genetic
T73828 802-808 UBERON:0002405;GO:0006955 denotes immune
T2948 809-817 GO:0006955 denotes response
T72804 897-905 SP_10 denotes SARS-CoV
T63585 910-918 SP_9 denotes MERS-CoV
T57772 1102-1110 SP_10 denotes SARS-CoV
T4874 1277-1286 DG_29 denotes ribavirin
T72833 1356-1360 SP_9 denotes MERS
T51389 1582-1587 SP_6;NCBITaxon:9606 denotes human
T46048 1642-1648 NCBITaxon:9606 denotes people
T87897 1868-1890 CHEBI:52217;CHEBI:52217 denotes pharmacological agents
T26480 1912-1920 SP_7 denotes COVID-19
T90542 2082-2086 CHEBI:23888;CHEBI:23888 denotes drug
T37163 2137-2142 NCBITaxon:10239 denotes viral
T76008 2176-2180 CHEBI:23888;CHEBI:23888 denotes drug
T1743 2315-2330 CHEBI:50858;CHEBI:50858 denotes corticosteroids
T19878 2354-2368 GO:0019814 denotes immunoglobulin
T42944 2441-2456 CHEBI:50858;CHEBI:50858 denotes corticosteroids
T66105 2499-2507 SP_7 denotes COVID-19
T10959 2587-2592 NCBITaxon:10239 denotes viral
T19275 2695-2703 SP_10 denotes SARS-CoV
T38092 2708-2716 SP_9 denotes MERS-CoV
T72801 2781-2789 SP_7 denotes COVID-19
T27059 2814-2818 PR:000001393 denotes IL-6
T36392 2830-2838 GO:0042571 denotes antibody
T43679 2840-2851 DG_35 denotes Tocilizumab
T33223 2881-2887 UBERON:0001969 denotes plasma
T78491 3094-3098 UBERON:0002048;GO:0030324 denotes lung
T78488 3099-3105 UBERON:0000479;GO:0048771 denotes tissue
T36301 3106-3112 GO:0006281 denotes repair
T56773 3219-3228 CL:0000034 denotes stem cell
T4596 3268-3276 SP_7 denotes COVID-19
T56143 3291-3302 UBERON:0001004 denotes respiratory

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
266 430-438 Species denotes patients Tax:9606
267 897-905 Species denotes SARS-CoV Tax:694009
268 910-918 Species denotes MERS-CoV Tax:1335626
269 1102-1110 Species denotes SARS-CoV Tax:694009
270 1582-1587 Species denotes human Tax:9606
271 1642-1648 Species denotes people Tax:9606
272 1277-1286 Chemical denotes ribavirin MESH:D012254
273 244-252 Disease denotes COVID-19 MESH:C000657245
274 818-830 Disease denotes inflammation MESH:D007249
275 1211-1215 Disease denotes ARDS MESH:D012128
289 2814-2818 Gene denotes IL-6 Gene:3569
290 2695-2703 Species denotes SARS-CoV Tax:694009
291 3153-3161 Species denotes patients Tax:9606
292 3277-3285 Species denotes patients Tax:9606
293 2840-2851 Chemical denotes Tocilizumab MESH:C502936
294 1912-1920 Disease denotes COVID-19 MESH:C000657245
295 2499-2507 Disease denotes COVID-19 MESH:C000657245
296 2599-2619 Disease denotes secondary infections MESH:D060085
297 2708-2727 Disease denotes MERS-CoV infections MESH:D018352
298 2781-2789 Disease denotes COVID-19 MESH:C000657245
299 3189-3193 Disease denotes ARDS MESH:D012128
300 3268-3276 Disease denotes COVID-19 MESH:C000657245
301 3291-3316 Disease denotes respiratory complications MESH:D012131

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T73 463-466 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T74 737-742 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T75 1995-1998 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T76 2354-2368 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T77 2830-2838 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T78 2881-2887 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T79 2903-2918 Body_part denotes immunoglobulins http://purl.org/sig/ont/fma/fma62871
T80 3094-3098 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T81 3099-3105 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T82 3219-3228 Body_part denotes stem cell http://purl.org/sig/ont/fma/fma63368
T83 3224-3228 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T19 463-466 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T20 1995-1998 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T21 3094-3098 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T22 3099-3105 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T80 244-252 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T81 818-830 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T82 897-905 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T83 897-901 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T84 1102-1110 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T85 1102-1106 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T86 1211-1215 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T87 1912-1920 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T88 2499-2507 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T89 2609-2619 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T90 2684-2693 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T91 2695-2703 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T92 2695-2699 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T93 2717-2727 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T94 2781-2789 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T95 3189-3193 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T96 3268-3276 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T113 56-62 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T114 98-99 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T115 463-466 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T116 721-726 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T117 737-742 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T118 995-999 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T119 1376-1380 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T120 1543-1544 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T121 1582-1587 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T122 1748-1749 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T123 1995-1998 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T124 2274-2275 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T125 2881-2887 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T126 3094-3098 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T127 3094-3098 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T128 3219-3228 http://purl.obolibrary.org/obo/CL_0000034 denotes stem cell

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T36 616-640 Chemical denotes anti-inflammatory agents http://purl.obolibrary.org/obo/CHEBI_67079
T37 1277-1286 Chemical denotes ribavirin http://purl.obolibrary.org/obo/CHEBI_63580
T38 1291-1301 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T39 2082-2086 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T40 2176-2180 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T41 2315-2330 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T42 2441-2456 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T43 2814-2816 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T17 802-817 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T18 818-830 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T19 3117-3129 http://purl.obolibrary.org/obo/GO_0031099 denotes regeneration

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T59 0-38 Sentence denotes Current Treatments Are Palliative Only
T60 39-291 Sentence denotes Despite over 300 active and recruiting clinical trials and a number of trials already completed, there is still no robust evidence that any of the investigated therapeutics are effective as treatments for COVID-19 disease (Channappanavar et al., 2017).
T61 292-386 Sentence denotes Equally, there is no evidence to support prophylactic treatment either (Sanders et al., 2020).
T62 387-497 Sentence denotes However, there are only 29 trials in adult patients with placebo-controlled arm (Channappanavar et al., 2017).
T63 498-641 Sentence denotes Various types of pharmacological treatments are currently under investigation including anti-viral, anti-malarial and anti-inflammatory agents.
T64 642-831 Sentence denotes These therapies generally target the following processes: (1) the entry of the virus into host cells, (2) multiplication of the viral genetic material, and (3) immune response/inflammation.
T65 832-1065 Sentence denotes Most of these agents have been previously used as treatments for SARS-CoV and MERS-CoV, however the overall conclusions of the meta-analyses published in 2006 and 2018, respectively, did not support the use of any particular regimen.
T66 1066-1248 Sentence denotes In relation to the meta-analysis of SARS-CoV treatments, the authors systematically reviewed 54 treatment studies, 15 in vitro studies and three ARDS studies (Stockman et al., 2006).
T67 1249-1458 Sentence denotes Although the combination of ribavirin and interferon-based (IFN) treatments appears the most effective for MERS (Morra et al., 2018), this needs to be confirmed in randomized placebo-controlled trial settings.
T68 1459-1728 Sentence denotes In terms of vaccines, there are at least 115 vaccine candidates in development with a number of these already initiated in human trials, however we expect vaccines to be available to people under emergency use only in early 2021 (Callaway, 2020; Thanh Le et al., 2020).
T69 1729-1921 Sentence denotes Overall, there are a number of concerns in relation to the design of various trials and interpretation of the data investigating different pharmacological agents for the treatment of COVID-19.
T70 1922-2189 Sentence denotes Some of these limitations include small cohort sizes, no placebo control arm, lack of considerations for gender, comorbidities, concurrent treatments, route of drug delivery, primary outcomes lacking effects on the viral load or suppression, and adverse drug effects.
T71 2190-2425 Sentence denotes Whilst most of these therapies represent supportive and symptomatic care, there are a number of adjunctive therapies such as corticosteroids, immunomodulatory, and immunoglobulin agents that have been investigated with limited results.
T72 2426-2751 Sentence denotes In particular, corticosteroids are not recommended for the management of COVID-19 because of the associated adverse effects, which potentially include increased viral load, secondary infections and complications, similarly to what was observed previously in influenza, SARS-CoV and MERS-CoV infections (Russell et al., 2020).
T73 2752-3040 Sentence denotes Potential benefits in severe COVID-19 cases are emerging with IL-6 monoclonal antibody, Tocilizumab, and the use of convalescent plasma or hyperimmune immunoglobulins, however better designs and further trials are needed for this to be established (Chen L. et al., 2020; Fu et al., 2020).
T74 3041-3317 Sentence denotes Nevertheless, none of these therapies are capable of lung tissue repair and regeneration, particularly in those patients with complications such as ARDS, which is why the use of stem cell-based therapies could be beneficial in COVID-19 patients with respiratory complications.

2_test

Id Subject Object Predicate Lexical cue
32574317-28373583-31466304 285-289 28373583 denotes 2017
32574317-32282022-31466305 380-384 32282022 denotes 2020
32574317-28373583-31466306 491-495 28373583 denotes 2017
32574317-16968120-31466307 1242-1246 16968120 denotes 2006
32574317-29664167-31466308 1376-1380 29664167 denotes 2018
32574317-32346146-31466309 1699-1703 32346146 denotes 2020
32574317-32273591-31466310 1722-1726 32273591 denotes 2020
32574317-32043983-31466311 2745-2749 32043983 denotes 2020
32574317-32113510-31466312 3017-3021 32113510 denotes 2020
32574317-32290839-31466313 3034-3038 32290839 denotes 2020

MyTest

Id Subject Object Predicate Lexical cue
32574317-28373583-31466304 285-289 28373583 denotes 2017
32574317-32282022-31466305 380-384 32282022 denotes 2020
32574317-28373583-31466306 491-495 28373583 denotes 2017
32574317-16968120-31466307 1242-1246 16968120 denotes 2006
32574317-29664167-31466308 1376-1380 29664167 denotes 2018
32574317-32346146-31466309 1699-1703 32346146 denotes 2020
32574317-32273591-31466310 1722-1726 32273591 denotes 2020
32574317-32043983-31466311 2745-2749 32043983 denotes 2020
32574317-32113510-31466312 3017-3021 32113510 denotes 2020
32574317-32290839-31466313 3034-3038 32290839 denotes 2020